v3.26.1
GRANT INCOME
 6 Months Ended
Jun. 30, 2026
GRANT INCOME  
GRANT INCOME

NOTE 10: GRANT INCOME

If restricted cash is received from grants in advance of incurring qualifying costs, it is recorded as deferred grant income and recognized as other income when qualifying costs are incurred. The Company had $0.6 million and $1.0 million of restricted cash recorded as of June 30, 2026 and December 31, 2025, respectively.

The following table summarizes grant income recorded for the three and six months ended June 30, 2026 and 2025, by grant:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

For the Three Months Ended

  ​ ​ ​

For the Six Months Ended

​

​

June 30,

​

June 30, 

​

 

2026

  ​ ​ ​

2025

​

2026

  ​ ​ ​

2025

Grant income:

 

​

​

​

​

​

​

​

​

 

​

​

CPRIT AML Grant1

​

$

256,890

​

$

319,610

​

$

465,399

​

$

537,254

FDA Grant

​

​

20,055

​

​

104,461

​

 

22,958

​

 

104,461

SBIR AML Grant

​

​

—

​

​

11,594

​

 

116,504

​

 

108,317

Decoy Grant

​

​

167,206

​

​

189,076

​

 

265,840

​

 

203,291

PANACEA Grant

​

​

105,601

​

​

53,168

​

 

179,079

​

 

61,147

CPRIT Pancreatic Grant1

​

​

131,827

​

​

183,275

​

 

383,490

​

 

195,818

Total grant income

​

$

681,579

​

$

861,184

​

$

1,433,270

​

$

1,210,288

(1) Both CPRIT grants are subject to certain revenue-sharing arrangements, as per the grant agreements (see Note 11).

If qualifying grant income is earned in advance of cash received from grants, it is recognized as other income and recorded as other receivable (see Note 6).